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40 days and 40 nights: Clinical 
characteristics of major trauma and 
orthopaedic injury comparing the 
incubation and lockdown phases of 
COVID-19 infection
Aims
The first death in the UK caused by COVID-19 occurred on 5 March 2020. We aim to describe 
the clinical characteristics and outcomes of major trauma and orthopaedic patients admit-
ted in the early COVID-19 era.
Methods
A prospective trauma registry was reviewed at a Level 1 Major Trauma Centre. We divided 
patients into Group A, 40 days prior to 5 March 2020, and into Group B, 40 days after.
results
A total of 657 consecutive trauma and orthopaedic patients were identified with a mean age 
of 55 years (8 to 98; standard deviation (SD) 22.52) and 393 (59.8%) were males. In all, 344 
(approximately 50%) of admissions were major trauma. Group A had 421 patients, decreas-
ing to 236 patients in Group B (36%). Mechanism of injury (MOI) was commonly a fall in 
351 (52.4%) patients, but road traffic accidents (RTAs) increased from 56 (13.3%) in group 
A to 51 (21.6%) in group B (p = 0.030). ICU admissions decreased from 26 (6.2%) in group 
A to 5 (2.1%) in group B. Overall, 39 patients tested positive for COVID-19 with mean age 
of 73 years (28 to 98; SD 17.99) and 22 (56.4%) males. Common symptoms were dyspnoea, 
dry cough, and pyrexia. Of these patients, 27 (69.2%) were nosocomial infections and two 
(5.1%) of these patients required intensive care unit (ICU) admission with 8/39 mortality 
(20.5%). Of the patients who died, 50% were older and had underlying comorbidities (hy-
pertension and cardiovascular disease, dementia, arthritis).
conclusion
Trauma admissions decreased in the lockdown phase with an increased incidence of RTAs. 
Nosocomial infection was common in 27 (69.2%) of those with COVID-19. Symptoms and 
comorbidities were consistent with previous reports with noted inclusion of dementia and 
arthritis. The mortality rate of trauma and COVID-19 was 20.5%, mainly in octogenarians, 
and COVID-19 surgical mortality was 15.4%.
Cite this article: Bone Joint Open 2020;1-7:330–338.
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introduction
On 30 January 2020, the World Health Orga-
nization (WHO) declared the coronavirus 
disease 2019 (COVID-19) as an outbreak of 
Public Health Emergency and International 
Concern.1 On 5 March 2020, over 100 cases 
were identified and the first official death in 
the UK occurred.2 On 11 March 2020, the 
Director General of the WHO characterized 
COVID-19 as a global pandemic caused by 
the viral pathogen Severe Acute Respiratory 
Syndrome Coronavirus 2 (SAR- CoV-2).1
Due to the highly infectious nature of 
the virus, some hospitals and healthcare 
systems have been overwhelmed.3 The UK 
government implemented social lockdown 
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with measures including social distancing and self- 
isolation. The rapidly changing situation caused hospi-
tals to continually update their healthcare management 
policies, including surgical management and ward 
based treatment. Elective surgery was suspended, with 
emergency and time- critical surgery, including trauma 
surgery, continuing.4 The British Orthopaedic Associa-
tion (BOA) published guidelines suggesting changes in 
approach to standard management practices so as to 
minimize patient exposure to the virus and reduce overall 
impact on resources.5
Currently there is a paucity of data on the clinical charac-
teristics and outcomes of the traumatically injured patient 
with COVID-19 infection. This is of importance in order 
to understand risk factors, comorbidities, multiplicity of 
infection (MOI), the anatomy at risk, and the surgical sub- 
specialties required. Redistribution of resources had an 
unanticipated impact on the healthcare system and the 
importance of understanding the clinical characteristics 
of traumatically injured COVID-19 patients could help to 
protect patients and staff. The challenge of the pandemic 
is the need to balance resources while considering the indi-
vidual, the population, the economy, and the supply of 
personal protective equipment (PPE) to prevent the possi-
bility of overwhelming healthcare systems.
The aim of this paper is to analyze and present the 
clinical characteristics of trauma patients presenting to a 
Level 1 major trauma centre during the early stages of the 
COVID-19 pandemic in the UK.
Methods
This single- centre, observational study was designed and 
reported according to STROBE guidance.6 A retrospective 
analysis of a prospectively collected trauma database was 
performed at our Level 1 trauma hospital in south west 
London providing specialist care for 3.5 million people. 
All clinical notes of major trauma and orthopaedic 
patients from 26 January 2020 to 14 April 2020 were 
reviewed. The first confirmed case of COVID-19 in the UK 
was on 28 February 2020. It is known that many asymp-
tomatic patients had travelled from infected regions 
into the UK prior to this. We refer to this period as the 
incubation phase. When SARS- CoV-2 severe pneumonia 
started to cause mortality on 5 March 2020, the virus was 
spreading exponentially, requiring governments around 
the world to begin imposing lockdown strategies. UK offi-
cial lockdown commenced on 23 March 2020. Even prior 
to official quarantine, many companies and professional 
bodies were commencing their own lockdown. This time 
period is referred to as the lockdown phase. Cases were 
divided into two groups: Group A (incubation phase), 
40 days before the first UK recorded death, and Group B 
(lockdown phase), 40 days after. No patient was directly 
involved in this study.
Inclusion criteria for major trauma was activation of 
the major trauma call or patients with orthopaedic inju-
ries requiring admission. Diagnosis of COVID-19 was by 
the hospital’s standard swabbing process of the nose and 
throat and on- site laboratory RNA confirmation. Clinical 
records were analyzed for diagnostics, pathology results, 
treatments and outcomes. COVID-19 cases were desig-
nated as Group C and non- COVID-19 cases as Group D.
Statistical analysis
Following verification of distributional assumptions of 
normality, groups were compared in continuous variables 
using the independent- samples t- test. When equality of 
variances could not be assumed between groups, Satter-
waite’s approximation to the degrees of freedom was 
made. When distributional assumptions could not be 
made, groups were compared in continuous variables 
using the Mann- Whitney U test (test statistic denoted by 
U). Groups were compared in categorical variables using 
the chi- squared test, and when invalid by using Fisher’s 
exact test. Traditional statistical hypothesis testing with a 
two- sided alternative was employed, with a critical level 
of significance of p < 0.05. No adjustments were made 
for multiple hypothesis testing. Analyses were performed 
using SPSS v. 26 (IBM, Armonk, New York, USA).
results
Overall, 657 consecutive trauma patients were included 
in this study. A total of 421 (64.1%) patients were 
admitted within the first 40 days (Group A: early incuba-
tion phase) versus 36 (35.9%) patients in the following 
40 days (Group B: early lockdown phase). There was a 
progressive decline in the number of patients per week in 
both groups (Figure 1).
Table  I shows the baseline characteristics of patients 
admitted under major trauma and orthopaedics (T & 
O) during the onset of the COVID-19 pandemic. Injury 
and demographics are shown. Both groups had a higher 
percentage of male patients, with falls and RTA’s being 
the most common mechanism of injury. Group B showed 
higher incidence of pelvis, chest and thorax, and spine inju-
ries (p < 0.050). ICU admissions were fewer in the lockdown 
phase: Group A (26; 6.2%) compared to group B (2.1%); 
p = 0.020.
A total of 39 patients tested positive for COVID-19 
by RNA swab tests with ten patients in Group A and 29 
in Group B. It is noted that there was 0% community 
acquired COVID-19 in Group A and 12 patients (5.1%) in 
Group B. Overall, there were 2.4% nosocomial infections 
in Group A and 7.2% in Group B. Within the COVID-19 
group, 69.2% (n = 27) were nosocomial infections.
Table II depicts the baseline characteristics of patients 
with COVID-19 infection (Group C) admitted under 
T & O in comparison to all non- COVID-19 (Group D) 
patients. The mean age in Group C was 73.2 years (28 
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Fig. 1
Number of cases admitted under major trauma and orthopaedics (T&O) during the COVID-19 pandemic. Group A (weeks 1 to 6) 40 days before 5 March 
2020 vs Group B (weeks 7 to 12) 40 days after 5 March 2020.
to 98; SD 17.99) versus 54.1 years (8 to 98; SD 22.3) in 
Group D. Group C shows that 32 (82.1%) patients were 
> 60 years versus 263 (42.6%) in Group D. There was 
no difference in ratio of sex between groups. Group 
C (COVID-19) had significantly higher percentage of 
comorbidities than Group D (non- COVID-19 patients): 
hypertension in 18 (46.2%), CVD in 14 (35.9%), arthritis 
in nine (23.1%), dementia in seven (17.9%), and malig-
nancy in six (15.4%). Diabetes (p = 0.072; Fisher's Exact 
test) and renal disease (p = 0.001; Fisher's Exact test) were 
not significantly different. Surgical intervention occurred 
less in Group C with 33.3% compared to 40.5% in Group 
D. Surgical mortality was higher in Group C (15.4%) 
compared to group D (2.8%).
Table III shows the type of orthopaedic procedures and 
surgical specialties that were involved with patients with 
COVID-19 compared to non- COVID-19 patients. Two 
patients (5.1%) required ICU admission and both recov-
ered. In total, 13 patients (33.3%) with COVID-19 infec-
tion underwent orthopaedic surgery with five (12.9%) 
requiring hip surgery. Neurosurgery was required in 12 
(30.8%) and cardiothoracic surgery in five (12.8%) patients 
with COVID-19 infection. Patients with COVID-19 infection 
had a significantly higher mortality 20.5% (n = 8) versus 
3.7% (n = 23) in non- COVID-19 patients (p < 0.010).
Table IV shows signs, symptoms and laboratory findings 
of COVID–19 patients. The most common symptoms were 
dyspnoea (56.4%), fever (20.5%) and dry cough (15.4%). 
Antibiotic treatment, oxygen support and laboratory find-
ings between survivors and non- survivors are shown.
Table V depicts clinical characteristics of eight patients 
with COVID-19 infection who died. 87.5% (7 out of 8) 
were nosocomial infections. These patients were elderly 
with a mean age of 84.4 years (p = 0.047) with 25% 
receiving surgery and no ICU admissions. Discussion
This is, to our knowledge, the first study describing 
the baseline clinical characteristics and outcomes of 
major trauma and orthopaedic injured patients with 
COVID-19 infection. We chose the pivotal timepoint of 5 
March 2020 as it represented the day of the first UK death 
from COVID-19 infection. The first known positive test 
in the UK was 31 January 20207 and Group A represents 
the early incubation period in this region. After the first 
death, measures were undertaken, though not stringent, 
until the official UK lockdown commenced on 23 March 
20208. There was a decrease of 56% in trauma admissions 
between these two times.
Falls remained the most common MOI, however the 
percentage of RTAs was significantly higher (p = 0.036). 
Anecdotal evidence suggested that empty roads were 
associated with higher speeding and there has been a call 
to lower speed limits to 20mph in urban areas.9
A contributing factor to decreased tertiary admissions 
lay in the recommendations from national guidelines to 
limit referrals to major trauma centres. Novel telemedi-
cine or video conferencing allowed expert specialist opin-
ions to deliver care locally and prevent transfer where 
appropriate.10
Surgery itself did not seem to be a risk factor for 
SARS- CoV-2 pneumonia. The incidence of surgery was 
40% (n = 263) across 657 patients, with one- third of 
COVID-19 patients and one- quarter of COVID-19 deaths 
undergoing surgery. In contrast to this, a study of 34 oper-
ative patients in Wuhan during the incubation period of 
COVID-19 suggests that surgery may have accelerated and 
exacerbated the disease progression due to patients devel-
oping symptoms shortly after surgery.11
There was a significantly higher ICU admission rate 
in Group A (6.2%) versus Group B (2.1%). These figures 
may reflect bed pressures. We had our peak of inpatient 
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Table i. Baseline characteristics of patients admitted under Orthopaedics during the onset of the COVID-19 pandemic.
Group A (n = 421) Group B (n = 236) Total (n = 657) p- value
Mean age, yrs (range) 55.6 (16 to 98) 54.6 (8 to 98) 55.3 (8 to 98) 0.598
Age, n (%)
 < 60 yrs 223 (53.0) 139 (58.9) 362 (55.1) 0.165
 > 60 yrs 198 (47.0) 97 (41.1) 295 (44.9) 0.165
Sex, n (%)
Female 169 (40.1) 95 (40.3) 264 (40.2) 0.978
Male 252 (59.9) 141 (59.7) 393 (59.8) 0.978
Admission type, n (%)
Major trauma 217 (51.5) 127 (53.8) 344 (52.4) 0.576
Orthopaedic 204 (48.5) 109 (46.2) 313 (47.6) 0.576
Moi 0.036
Fall 230 (54.6) 121 (51.3) 351 (53.4)
RTA 56 (13.3) 51 (21.6) 107 (16.3)
Pain 38 (9.0) 16 (6.8) 54 (8.2)
Assault 31 (7.4) 14 (5.9) 45 (6.8)
Self- harm 18 (4.3) 6 (2.5) 24 (3.7)
Wound infection 11 (2.6) 6 (2.5) 17 (2.6)
Accidental 5 (1.2) 9 (3.8) 14 (2.1)
Sport 8 (1.9) 3 (1.3) 11 (1.7)
Twisting 3 (0.7) 3 (1.3) 6 (0.9)
Malignancy 1 (0.2) 2 (0.8) 3 (0.5)
Unknown 20 (4.8) 5 (2.1) 25 (3.8)
injury anatomy
LL 120 (28.5) 53 (22.5) 173 (26.3) 0.091
UL 97 (23.0) 65 (27.5) 162 (24.7) 0.199
Thorax and abdomen 78 (18.5) 60 (25.4) 138 (21.0) 0.037
Pelvic 65 (15.4) 53 (22.5) 118 (18.0) 0.025
Head and neck 63 (15.0) 49 (20.8) 112 (17.0) 0.058
Spinal 45 (10.7) 43 (18.2) 88 (13.4) 0.007
intervention
Conservative 250 (59.4) 144 (61.0) 394 (60.0) 0.682
Surgical 171 (40.6) 92 (39.0) 263 (40.0) 0.682
Surgical speciality
Orthopaedic 158 (37.5) 75 (31.8) 233 (35.5) 0.139
Plastics 7 (1.7) 8 (3.4) 15 (2.3) 0.155
Neurosurgery 1 (0.2) 4 (1.7) 5 (0.8) 0.059†
General surgery 3 (0.7) 2 (0.8) 5 (0.8) 1.000†
Maxillofacial 1 (0.2) 2 (0.8) 3 (0.5) 0.294†
Cardiothoracic 1 (0.2) 0 (0.0) 1 (0.2) 1.000†
ENT 0 (0.0) 1 (0.4) 1 (0.2) 0.359†
ICU admissions 26 (6.2) 5 (2.1) 31 (4.7) 0.020
Mortality 15 (3.6) 16 (6.8) 31 (4.7) 0.083
COVID-19 positive 10 (2.4) 29 (12.3) 39 (5.9) < 0.001
Community infection 0 (0.0) 12 (5.1) 12 (1.8) 0.017†
Nosocomial infection 10 (2.4) 17 (7.2) 27 (4.1) 0.017†
*The test statistics are for the null hypothesis significance test for the comparison of Group A with Group B. ‡ Fisher’s Exact test conducted due to invalid 
Chi- Squared test. Group A, incubation phase; Group B, lockdown phase. Statistically significant.
MOI, mechanism of injury; RTA, road traffic accident; LL, lower limb; UL, upper limb; ENT, ear, nose and throat; ICU, intensive care unit; NA, not applicable; 
CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease
admissions (310 COVID-19 inpatients) on 2 April and 
our hospital peaked with 83 ICU patients on 19 April 
(Figure 2).
Stringent treatment escalation plans may also have 
persuaded families and patients to avoid ICU admission 
which caused nursing staff to issue warnings against 
blanket DNACPR notices.12
COVID-19 in our cohort had a similar preponder-
ance for sex which correlates to a study in China on 135 
patients,13 whereas other reports have quoted males at 
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Table ii. Baseline characteristics of patients with COVID-19 infection admitted under Orthopaedics.
Total (n = 657) Group c: coViD-19 (n = 39) Group D: non- coViD-19 (n = 618) p- value
Age, yrs
Mean (SD; range) 55.3 (22.53; 8 to 98) 73.2 (17.99; 28 to 98) 54.1 (22.3) <0.001$*
Median 57.0 (95% CI 13.0 to 25.2) 73.2 55.0 < 0.001
< 60 years, n (%) 362 (55.1) 7 (17.9) 355 (57.4) < 0.001
> 60 years, n (%) 295 (44.9) 32 (82.1) 263 (42.6) < 0.001
Sex n (%)
Female 264 (40.2) 17 (43.6) 247 (40.0) 0.737
Male 393 (59.8) 22 (56.4) 371 (60.0) 0.737
comorbidity, n (%)
Hypertension 153 (23.3) 18 (46.2) 135 (21.8) 0.001
CVD 90 (13.7) 14 (35.9) 76 (12.3) < 0.001
Arthritis 70 (10.7) 9 (23.1) 61 (9.9) 0.027‡
Diabetes 75 (11.4) 8 (20.5) 67 (10.8) 0.072‡
Dementia 52 (7.9) 7 (17.9) 45 (7.3) 0.027‡
Malignancy 43 (6.5) 6 (15.4) 37 (6.0) 0.035‡
COPD 29 (4.4) 4 (10.3) 25 (4.0) 0.086‡
Kidney disease 121 (18.4) 4 (10.3) 117 (18.9) 0.206
Asthma 99 (15.1) 2 (5.1) 97 (15.7) 0.102
intervention, n (%)
Surgical 263 (40.0) 13 (33.3) 250 (40.5) 0.405
Conservative 394 (60.0) 26 (66.7) 368 (59.5) 0.405
Surgical Mortality 9 (3.4) 2 (15.4) 7 (2.8) 0.089‡
*The test statistics are for the null hypothesis significance test for thecomparison of the COVID patients with non- COVID patients. $Satterwaite’s 
approximation to the degrees of freedom used; ‡Fisher’s Exact test conducted due to invalid Chi- Squared test; Statisitically significant.
CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease
Table iii. Types of surgery and specialties involved.
Surgery Total (n = 657) Group c: coViD-19 (n = 39) Group D: non- coViD-19 (n = 618) p- value
orthopaedic procedures, n (%)
ORIF 99 (15.1) 4 (10.3) 95 (15.4) 0.493
Hemi 20 (3.0) 4 (10.3) 16 (2.6) 0.026‡
DHS 15 (2.3) 1 (2.6) 14 (2.3) 0.605‡
Intramedullary nail 31 (4.7) 2 (5.1) 29 (4.7) 0.705‡
Exploration 17 (2.6) 0 (0.0) 17 (2.8) 0.616‡
Debridement & washout 31 (4.7) 2 (5.1) 29 (4.7) 0.705‡
MUA 2 (0.3) 0 (0.0) 2 (0.3) 1.000‡
Ex- fix 5 (0.8) 0 (0.0) 5 (0.8) 1.000‡
Tendon repair 9 (1.4) 0 (0.0) 9 (1.5) 1.000‡
Arthroscopy 4 (0.6) 0 (0.0) 4 (0.6) 1.000‡
Total 233 (35.4) 13 (33.3) 220 (35.6) 1.000‡
Specialities involved, n (%)
Plastics 24 (3.7) 0 (0.0) 24 (3.9) 0.389‡
Cardiothoracic 55 (8.4) 5 (12.8) 50 (8.1) 0.363‡
Neurosurgery/spine 129 (19.6) 12 (30.8) 117 (18.9) 0.094‡
General surgery 41 (6.2) 2 (5.1) 39 (6.3) 1.000‡
Maxillofacial 19 (2.9) 2 (5.1) 17 (2.8) 0.313‡
ENT 4 (0.6) 0 (0.0) 4 (0.6) 1.000‡
ICU admissions 31 (4.7) 2 (5.1) 29 (4.7) 0.693‡
Mortality 31 (4.7) 8 (20.5) 23 (3.7) < 0.000‡
*The test statistics are for the null hypothesis significance test for thecomparison of the COVID patients with non- COVID patients. ‡Fisher’s Exact test 
conducted due to invalid Chi- Squared test. Statistically significant.
ORIF, open reduction internal fixation; DHS, dynamic hip screw; MUA, manipulation under anaesthesia; ENT, ear, nose, throat; ICU, intensive care unit.
higher risk.14 The comorbidities in COVID-19 patients 
compared to noninfected patients were hypertension, 
cardiovascular disease, dementia, cancer, and arthritis. 
Arthritis has not previously been reported. Unlike other 
reports diabetes was not prevalent. While body mass 
index and ethnicity are noted to be factors influencing 
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Table iV. Signs, symptoms and laboratory findings of COVID -19- positive patients.
reference range Total (n = 39) Survival (n = 31) non- survival (8) p- value
Median age, yrs (range) 80 (28 to 98) 76 (28 to 90) 89 (62 to 98) 0.047
Age, n (%)
 < 60 years NA 7 (17.9) 7 (22.6) 0 (0) 0.308
 > 60 years NA 32 (82.1) 24 (77.4) 8 (100) 0.308
Signs and symptoms, n (%)
Fever NA 8 (20.5%) 7 (22.6%) 3 (37.5%) 0.399‡
Dry cough NA 6 (15.4%) 8 (25.8%) 3 (57.5%) 0.663‡
Dyspnoea NA 22 (56.4%) 16 (51.6%) 7 (87.5%) 0.109‡
Fatigue NA 4 (10.3%) 11 (35.9%) 5 (62.5%) 0.235‡
onset of infection, n (%)
Community NA 12 (30.8) 11 (35.5) 1 (12.5) 0.394‡
Nosocomial NA 27 (69.2) 20 (64.5) 7 (87.5) 0.394‡
Median laboratory findings (range)
White cell count × 10^9/l 3.6 to 11.0 7.5 (5.4 to 9.4) 7.1 ( 5.4 to 8.4) 8.6 (5.3 to 14.6) 0.401
Neutrophil count × 10^9/l 1.8 to 7.5 4.4 (3.6 to 6.5) 4.4 (3.5 to 6.4) 7.3 (3.8 to 12.6) 0.132
Lymphocyte count × 10^9/l 1.0 to 4.0 0.9 (0.7 to 1.0) 0.9 (0.7 to 1.1) 0.8 (0.6 to 0.9) 0.346
Monocyte count x 10^9/l 0.2 to 0.8 0.5 (0.4 to 0.7) 0.5 (0.4 to 0.7) 0.6 (0.3 to 1.1) 0.527
Platelet count × 10^9/l 140 to 400 230 (139 to 313) 220 (134 to 294) 314.5 (230.5 to 477.3) 0.052
Creatine, umol//l 60 to 110 75.0 (51 to 98) 72 (51 to 96) 109.5 (46.5 to 327.0) 0.249
C- reactive protein, mg/l < 5 74.0 (37 to 135) 56 (32 to 119) 196 (129.0 to 326.5) < 0.001
INR 0.8 to 1.2 1.1 (1.0 to 1.3) 1.1 (1.0 to 1.3) 1.3 (1.1 to 1.7) 0.044
Urea, mmol/L 2.5 to 7.8 5.9 (4.5 to 9.0) 5.8 (4.3 to 7.7) 14.75 (5.2 to 34.6) 0.048
Bilirubin, umol/L < 21 8 (6 to 14) 8 (6 to 11) 11 (5.8 to 15) 0.462
Alanine transaminase, U/L < 36 30 (21 to 45) 27 (19 to 38) 44 (33.8 to 56) 0.099
Alkaline phosphatase, IU/L 30 to 130 100 (76 to 178) 96 (74 to 154) 159 (91.3 to 257.3) 0.550
Albumin, g/L 35 to 50 25 (21.8 to 31.0) 25.5 (23 to 31.5) 20 (18.3 to 24) 0.132
Haemoglobin, g/L 115 to 180 108 (92 to 125) 108 (92 to 108) 101.5 (86.5 to 120) 0.021
Treatment, n (%)
Antibiotics N/A 13 (33.3) 9 (29) 4 (50) 0.402‡
Antiviral therapy N/A 2 (5.1) 2 (6.5) 0 1.000‡
Steroids N/A 2 (5.1) 2 (6.5) 0 1.000‡
oxygen support, n (%)
Nasal cannula N/A 21 (53.8) 11 (35.5) 8 (100) < 0.001‡
Noninvasive ventilator N/A 10 (25.6) 5 (16.1) 5 (62.5) < 0.001‡
Ventilator N/A 3 (7.7) 2 (6.4) 1 (12.5) < 0.001‡
HLOS NA 22 (11 to 28) 24 (11 to 28) 17.5 (9.3 to 34.3) 0.670
*For laboratory findings and HLOS, the median plus interquartile range is presented. The test statistics are for the null hypothesis significance test for the 
comparison of the survival with the non- survival patients. ‡Fisher’s Exact test conducted due to invalid Chi- Squared test. Statistically significant.
N/A, not applicable; HLOS, hospital length of stay; INR, international normalized ratio.
outcome in COVID-19, we were not able to include these 
due to incomplete data.15
Trauma patients with COVID-19 infection were signifi-
cantly (p < 0.001) older (mean 73.2 years; 28 to 98) and 
had one or more underlying comorbidities. Jordan et al16 
reported that 25% of people are labelled high risk in the 
UK, including adults aged over 70 years in addition to 
people with underlying health conditions such as cardio-
vascular, respiratory disease, and cancer. Based on data 
in our study, no children were discovered with corona-
virus and we show that during this time major trauma 
was uncommon in children. In support of these findings, 
reports from the Chinese Centre for Disease Control and 
Prevention showed that among 44,672 confirmed cases, 
most patients were 30 to 79 years, 1% were aged nine 
years or younger, 1% were aged ten to 19 years, and 3% 
were aged 80 years or older.17
The 39 patients in our study who developed COVID-19 
had similar symptoms and presentation to those reported 
in other studies.11,18
Patients received antibiotics if indicative with the SAR- 
CoV-2 severe pneumonia. Supportive therapy was the 
main course of action including non- invasive ventila-
tion (NIV) (25.6%; n = 10) and three patients ventilated 
(7.7%). There is currently no medication for the treat-
ment of COVID-19 and the therapeutic strategies are only 
supportive.
There was increased C reactive protein in COVID-19 
patients and in addition, the non- survival group had 
more deranged urea and Hb. White cell, neutrophil, and 
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Table V. Clinical characteristics of eight non- survival patients with COVID-19 infection.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 n (%)
DOA 19 March 27 February 9 March 29 February 10 March 26 January 25 March 7 March N/A
Age, yrs 62 73 80 89 89 90 94 98 N/A
Sex, male/female Male Male Male Female Female Female Male Female 4:4
comorbidities
CVD Yes Yes No No Yes Yes Yes Yes 6
HTN Yes No No No No No No Yes 2
Diabetes Yes No No No No No Yes No 2
Kidney disease Yes No Yes No No Yes No No 3
COPD No Yes No No No No No No 1
Dementia No No Yes Yes No Yes No No 3
Admission type
Trauma No No Yes Yes Yes No Yes No 4
Orthopaedics Yes Yes No No No Yes No Yes 4
MOI Pain Pain Fall Fall Fall Fall Fall Fall N/A
injury
Head & neck No No Yes No Yes No No Yes 3
Thorax No No No Yes Yes No No No 2
Spinal No No No Yes Yes No Yes No 3
Pelvic Yes No No No Yes No No Yes 3
UL No No No Yes No Yes No No 2
LL No Yes No No No No No No 1
intervention
Surgery No No No No Yes No No Yes 2
Conservative Yes Yes Yes Yes No Yes Yes No 6
Surgical Intervention N/A N/A N/A N/A Sacral fixation N/A N/A Hemi 2
Date of surgery N/A N/A N/A N/A 11 March N/A N/A 8 March N/A
coViD-19 onset
Community No No No No No No Yes No 1
Nosocomial Yes Yes Yes Yes Yes Yes No Yes 7
First symptom Fever Dyspnoea Dyspnoea Fever Dyspnoea Cough Cough Dyspnoea N/A
Date of swab test 21 March 27 March 25 March 15 March 25 March 11 March 26 March 15 March N/A
Complication ARDS ARDS ACS ARDS Resp failure Resp failure ARDS Resp failure N/A
Date of death 20 March 6 April 6 March 20 March 28 March 21 March 1 April 20 March N/A
HLOS 8 39 17 20 18 55 7 13 N/A
CVD, cardiovascular disease; HTN, hypertension; MOI, mechanism of injury; UL, upper limb; LL, lower limb; HLOS, hospital length of stay; Hemi, 
hemiarthroplasty; Resp, respiratory; ACS, acute coronary syndrome; ARDS, acute respiratory distress syndrome
lymphocyte counts were normal. Biomarkers have been 
explored in the early stage of COVID-19 to determine 
the severity. Results showed CRP levels were significantly 
compared to the severity of illness and greater size of 
lung lesions. C reactive protein reflects disease severity 
in the early stages.19 Our data shows a marked increase 
in later stages associated with severe SAR- CoV-2 pneu-
monia deaths.
The mortality rate increased between groups in the 
incubation phase and lockdown phase (3.6% (n = 15) and 
6.8% (n = 16)), but this did not reveal statistical signif-
icance. However, the mortality of patients infected by 
COVID-19 was 20.5% compared to non- infected patients 
of 3.7% which was significantly higher. COVID-19 surgical 
mortality is as high as 27.3% with thoracic surgery.20 
Our surgical mortality in patients with COVID-19 was 
15.4% (n = 2) in contrast to Bhangu et al21 who reported 
on 1,128 patients in 24 countries with a mortality rate 
of 23.8%, Of note, their mortality rate was composed 
of 75% emergency and 25% elective surgeries, whereas 
our data only represents emergencies. In contrast to our 
COVID-19 surgical mortality, the non- COVID-19 surgical 
mortality was only 2.8% (n = 7).
ICU admission rate during the lockdown phase was 
2.1% (n = 5), which was significantly (p = 0.020) lower 
than patients during incubation phase (6.2%). Only 
5.1% (n = 2) of COVID-19 patients were admitted to ICU. 
Critical care triage to allow the rationing of scarce ICU 
resources have been required in some countries.22–24 We 
know from our hospital data that we were never over-
whelmed by the pandemic. Ward inpatients peaked at 
over 300 and almost 90 ICU admissions, yet our capacity 
was 420 ventilated beds with a further 100 possible. 
Therefore, a rise in mortality but decrease in ICU admis-
sions for our cohort of traumatically injured was not an 
ICU bed capacity/resource issue.
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Fig. 2
Total number of COVID-19 positive inpatient figures at our hospital during the period of 26 February to 14 April 2020.
Overall, 39 (5.9%) of patients in our study tested 
positive for COVID-19 infection. Of these 39 patients, 
27 (69.2%) patients acquired their infection during their 
admission in hospital. Nosocomial infection was to be 
expected given the contagious infectivity.25 Our figure is 
higher than the reported literature with a meta- analysis 
showing a COVID-19 nosocomial infection rate of 44%.26 
It is interesting to see a 70% nosocomial infection within 
the coronavirus cohort, but perhaps not surprising given 
their risk factors of age, comorbidities, as well as the 
immunosuppression associated with major trauma.
COVID-19 tests were not initially performed on asymp-
tomatic admissions in our institution nor were health-
care providers routinely screened. Only five (12.8%) had 
definite positive swabs on admission and positive swabs 
occurred in an average of 12.3 days (mean 12.3; 0 to 45). 
In contrast, Wong et al27 showed that with vigilant contact 
tracing nosocomial transmission may be controlled 
and was unlikely an airborne disease. COVID-19 virus 
is primarily transmitted between people through respi-
ratory droplets (> 5 um) and contact routes.28 Airborne 
transmission may occur if aerosol generating medical 
procedures (AGMP) transmit particles which may remain 
airborne longer. Rivett et al29 showed only 3% of asymp-
tomatic healthcare workers tested positive, suggesting 
our assumed asymptomatic patients on admission were 
true nosocomial infections. With multiple transmission 
routes, there are multiple factors to contribute to our 
high nosocomial infection rate. Recommendations of 
adequate indoor ventilation to remove virus laden respi-
ratory droplets have been made.30
Our study reveals that eight trauma patients died 
with COVID-19 compared to 31 patients who survived. 
We show that patients who died were older (mean 
84.4 years) and had multiple comorbidities (cardio-
vascular disease, hypertension, dementia, diabetes). In 
one meta- analysis of seven studies it was reported that 
hypertension, respiratory system disease and cardiovas-
cular disease were risk factors.31 In another study, Lei et 
al11 showed that hypertension and cardiovascular disease 
were the most common comorbidities of seven patients 
that died of COVID-19, in keeping with our study.
The limitations of this study include the small sample 
size of positive COVID-19 patients. However, this figure is in 
keeping with international figures, if not higher than from 
some of the highest incidence centres in the literature.11 
Numbers may have decreased at our centre secondary 
to national guidelines to reduce referrals to major trauma 
centres; however, suitable cases were always transferred.10 
National and local guidelines dictated that only symp-
tomatic patients were tested on admission.32 Lack of PPE 
in this country did not seem to be a major issue at our 
hospital although the frequently changing protocols may 
have contributed. Aerosol and contact transmission may 
play a role in the hospital environment but are difficult to 
measure. Statistical relevance must be carefully considered 
due to the small sample numbers but benefit from the 
large comparison cohort.
Major trauma will inevitably still occur in a pandemic 
where lockdown and social distancing have been 
imposed. While the numbers may decline, major trauma 
and orthopaedic injuries will account for regular admis-
sions to hospital. This has implications for the spread 
of COVID-19. Our data shows that the total number of 
trauma patients with COVID-19 (5.9%; n = 39) was small, 
but rose from 2.4% (n = 10) in the incubation phase to 
12.3% (n = 29) during the lockdown phase. It affects 
equal preponderance of males to females and the older 
age group (over 70 years). Their most common injuries 
were pelvic, chest and spine caused mainly by falls but 
also from an increased incidence of RTA. One- third were 
treated surgically. Our study confirms that symptoms 
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mainly included dyspnoea, dry cough, and pyrexia. 
Common comorbidities included hypertension, CVD, 
dementia, arthritis, and malignancy, but not diabetes. 
Trauma patients with COVID-19 have a high incidence 
of nosocomial infection (69.2%; n = 27) but also a high 
mortality rate (20.5%) in octogenarians. Our surgical 
COVID-19 mortality was 15.3%, moderately lower in 
comparison to other reports, but five- times greater than 
our non- COVID-19 surgical mortality, underlining the 
risk of COVID-19 infection with surgery.
Twitter
Follow B. Ajayi @Bee_Aj1
Follow D. F. Lui @Darren_Lui
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